Clinical and Molecular Hepatology10.3350/cmh.2022.04222023292320-331Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectivesShang-Chin Huang, Chun-Jen Liu,,
Journal of Hepatology10.1016/j.jhep.2021.02.0132021751236-238Dynamics of liver stiffness in chronic hepatitis B patients with concurrent metabolic-associated fatty liver diseaseDanny Con, Daniel Clayton-Chubb, John Lubel, Rohit Sawhney, Stephen Bloom,
Journal of the Formosan Medical Association10.1016/j.jfma.2022.07.0132022121112148-2151Metabolic dysfunction-associated fatty liver disease and chronic hepatitis BShang-Chin Huang, Jia-Horng Kao,
10.21203/ of fatty liver index as a marker for metabolic dysfunction-associated fatty liver diseaseA lum Han,
10.21203/ of Fatty Liver Index as a Marker for Metabolic Dysfunction-Associated Fatty Liver DiseaseA lum Han, Youngjon Kim,
10.21203/ of Fatty Liver Index as a Marker for Metabolic Dysfunction-associated Fatty Liver DiseaseA lum Han, Youngjon Kim,
Clinical Liver Disease10.1002/cld.12502022205157-161The Shift from nonalcoholic fatty liver disease to metabolic dysfunction–associated fatty liver diseaseRochelle Wong, Brett E. Fortune,,
eBioMedicine10.1016/j.ebiom.2021.103584202172103584What the New Definition of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Left Behind: Genetically Acquired Fatty Liver Disease (GAFLD)Fernando Bril,
Alimentary Pharmacology & Therapeutics10.1111/apt.172702022572270-271Editorial: chronic hepatitis C with metabolic dysfunction‐associated fatty liver disease — a model for adoption of Sustainable Development Goal 3Oyekoya Ayonrinde, Richard Goodheart,,
Nephrology Dialysis Transplantation10.1093/ndt/gfac1882022383700-711Metabolic dysfunction–associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver diseaseMarenao Tanaka, Kazuma Mori, Satoko Takahashi, Yukimura Higashiura, Hirofumi Ohnishi, Nagisa Hanawa, Masato Furuhashi,,